Table 4. MiR-31-3p and miR-31-5p validated on the complete set of cetuximab samples from training set and validation set 1 (N = 69) and their correlation with TTP (weeks).
MiRNA | Patients (N = 69) | Median TTP (weeks) | Log-Rank P | Adjusted HR | 95% CI | P |
---|---|---|---|---|---|---|
MiR-31-3p | ||||||
Low, ≤ 0.0155 | 46 | 44 | <0.0001 | 5.099 | 2.520 to 10.317 | <0.001 |
High, > 0.0155 | 23 | 14 | ||||
MiR-31-5p | ||||||
Low, ≤ 0.1378 | 42 | 45 | <0.0001 | 4.803 | 2.497 to 9.242 | <0.001 |
High, > 0.1378 | 27 | 14 |